A carregar...
Update on PARP Inhibitors in Breast Cancer
The single agent activity of PARP inhibitors (PARPi) in germline BRCA mutated (gBRCAm) breast and ovarian cancer suggests untapped potential for this new class of drug in breast cancer. The US Food and Drug Administration has approved three PARPi (olaparib, rucaparib, and niraparib) so far to treat...
Na minha lista:
| Publicado no: | Curr Treat Options Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7430202/ https://ncbi.nlm.nih.gov/pubmed/29644491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-018-0540-2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|